text: <unk>  is a adeno-associated virus vector-based gene therapy that is FDA approved for the treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells as determined by the treating physician(s).   Common adverse reactions include conjunctival hyperemia, cataract, increased intraocular pressure, retinal tear, dellen (thinning of the corneal stroma), macular hole, subretinal deposits, eye inflammation, eye irritation, eye pain, and maculopathy (wrinkling on the surface of the macula).
option_0: Voretigene neparvovec
option_1: Mecasermin rinfabate
option_2: Masoprocol
option_3: Crofelemer
option_4: Telotristat ethyl
option_5: Levonorgestrel 
option_6: Ulipristal acetate
option_7: Tegaserod